TY - CHAP
T1 - Genome Editing Tools for Lysosomal Storage Disorders
AU - Gonzalez, Esteban Alberto
AU - Nader, Helena
AU - Siebert, Marina
AU - Suarez, Diego A.
AU - Alméciga-Díaz, Carlos J.
AU - Baldo, Guilherme
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive license to Springer Nature Switzerland AG.
PY - 2023
Y1 - 2023
N2 - Genome editing has multiple applications in the biomedical field. They can be used to modify genomes at specific locations, being able to either delete, reduce, or even enhance gene transcription and protein expression. Here, we summarize applications of genome editing used in the field of lysosomal disorders. We focus on the development of cell lines for study of disease pathogenesis, drug discovery, and pathogenicity of specific variants. Furthermore, we highlight the main studies that use gene editing as a gene therapy platform for these disorders, both in preclinical and clinical studies. We conclude that gene editing has been able to change quickly the scenario of these disorders, allowing the development of new therapies and improving the knowledge on disease pathogenesis. Should they confirm their hype, the first gene editing-based products for lysosomal disorders could be available in the next years.
AB - Genome editing has multiple applications in the biomedical field. They can be used to modify genomes at specific locations, being able to either delete, reduce, or even enhance gene transcription and protein expression. Here, we summarize applications of genome editing used in the field of lysosomal disorders. We focus on the development of cell lines for study of disease pathogenesis, drug discovery, and pathogenicity of specific variants. Furthermore, we highlight the main studies that use gene editing as a gene therapy platform for these disorders, both in preclinical and clinical studies. We conclude that gene editing has been able to change quickly the scenario of these disorders, allowing the development of new therapies and improving the knowledge on disease pathogenesis. Should they confirm their hype, the first gene editing-based products for lysosomal disorders could be available in the next years.
UR - http://www.scopus.com/inward/record.url?scp=85172005801&partnerID=8YFLogxK
U2 - 10.1007/978-3-031-33325-5_8
DO - 10.1007/978-3-031-33325-5_8
M3 - Chapter
C2 - 37486520
AN - SCOPUS:85172005801
T3 - Advances in Experimental Medicine and Biology
SP - 127
EP - 155
BT - Advances in Experimental Medicine and Biology
PB - Springer
ER -